A. M. Storniolo

877 total citations
16 papers, 643 citations indexed

About

A. M. Storniolo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, A. M. Storniolo has authored 16 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 3 papers in Genetics. Recurrent topics in A. M. Storniolo's work include Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). A. M. Storniolo is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). A. M. Storniolo collaborates with scholars based in United States, Switzerland and United Kingdom. A. M. Storniolo's co-authors include Anne Nguyen, Todd C. Skaar, Zereunesay Desta, Yan Jin, D M Nikoloff, Lijun Wu, L LI, Brant R. Ward, Harold J. Burstein and María Koehler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

A. M. Storniolo

16 papers receiving 621 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. M. Storniolo United States 8 391 262 260 113 106 16 643
Roswitha Kammler Switzerland 9 444 1.1× 263 1.0× 185 0.7× 118 1.0× 64 0.6× 26 721
BA Parker United States 6 141 0.4× 187 0.7× 179 0.7× 110 1.0× 96 0.9× 8 440
Vincent O. Dezentjé Netherlands 18 592 1.5× 420 1.6× 358 1.4× 195 1.7× 127 1.2× 54 1.2k
Linda P. Briley United States 10 120 0.3× 155 0.6× 182 0.7× 255 2.3× 46 0.4× 21 672
Sara Margolin Sweden 15 316 0.8× 279 1.1× 77 0.3× 223 2.0× 19 0.2× 39 733
Mitul Shah United Kingdom 16 337 0.9× 286 1.1× 61 0.2× 389 3.4× 37 0.3× 22 967
Lang Li China 12 188 0.5× 173 0.7× 79 0.3× 389 3.4× 30 0.3× 21 720
Pia Wegman Sweden 10 281 0.7× 334 1.3× 313 1.2× 207 1.8× 14 0.1× 14 635
Anne‐Joy M. de Graan Netherlands 12 282 0.7× 64 0.2× 154 0.6× 74 0.7× 20 0.2× 16 425
Andrea M. Nibbe United States 7 354 0.9× 306 1.2× 225 0.9× 200 1.8× 11 0.1× 9 717

Countries citing papers authored by A. M. Storniolo

Since Specialization
Citations

This map shows the geographic impact of A. M. Storniolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. M. Storniolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. M. Storniolo more than expected).

Fields of papers citing papers by A. M. Storniolo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. M. Storniolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. M. Storniolo. The network helps show where A. M. Storniolo may publish in the future.

Co-authorship network of co-authors of A. M. Storniolo

This figure shows the co-authorship network connecting the top 25 collaborators of A. M. Storniolo. A scholar is included among the top collaborators of A. M. Storniolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. M. Storniolo. A. M. Storniolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bhat‐Nakshatri, Poornima, Hongyu Gao, Xiaoling Xuei, et al.. (2020). A Single Cell Atlas of the Healthy Breast Tissues Reveal Clinically Relevant Clusters of Breast Epithelial Cells. SSRN Electronic Journal. 1 indexed citations
2.
Latham-Mintus, Kenzie, et al.. (2017). EXPLORING CUMULATIVE DISADVANTAGE, TELOMERE LENGTH, AND BREAST CANCER AMONG BLACK AND WHITE WOMEN. Innovation in Aging. 1(suppl_1). 1338–1338. 1 indexed citations
3.
Anders, Carey K., Rachita Nanda, Kim T. Blackwell, et al.. (2011). TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM).. Journal of Clinical Oncology. 29(15_suppl). TPS127–TPS127. 3 indexed citations
4.
5.
Lin, NU, Naren Ramakrishna, A. M. Storniolo, et al.. (2010). Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 1154–1154. 10 indexed citations
6.
7.
Henry, N. Lynn, Anne Nguyen, Faouzi Azzouz, et al.. (2009). Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. British Journal of Cancer. 102(2). 294–300. 9 indexed citations
8.
Henry, N. Lynn, P. Charles, An Nguyen, et al.. (2009). A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms.. Cancer Research. 69(2_Supplement). 1129–1129. 4 indexed citations
9.
O’Shaughnessy, J., K. L. Blackwell, Harold J. Burstein, et al.. (2008). A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Journal of Clinical Oncology. 26(15_suppl). 1015–1015. 109 indexed citations
10.
Storniolo, A. M., María Koehler, A. Preston, et al.. (2007). Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA). Journal of Clinical Oncology. 25(18_suppl). 514–514. 10 indexed citations
11.
Desta, Zereunesay, L LI, Todd C. Skaar, et al.. (2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clinical Pharmacology & Therapeutics. 80(1). 61–74. 371 indexed citations
12.
Storniolo, A. M., et al.. (2005). Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: Interim analysis. Journal of Clinical Oncology. 23(16_suppl). 724–724. 5 indexed citations
13.
Storniolo, A. M., Howard A. Burris, Mark D. Pegram, et al.. (2005). A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. Journal of Clinical Oncology. 23(16_suppl). 559–559. 46 indexed citations
14.
Burstein, Harold J., Mark D. Pegram, A. M. Storniolo, et al.. (2005). Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 3004–3004. 56 indexed citations
15.
Goulet, Robert J., et al.. (2004). Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (NP) via InDuct@ Breast Microcatheter (IDBM). Journal of Clinical Oncology. 22(14_suppl). 828–828. 4 indexed citations
16.
Goulet, Robert J., et al.. (2004). Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (NP) via InDuct@ Breast Microcatheter (IDBM). Journal of Clinical Oncology. 22(14_suppl). 828–828. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roswitha Kammler Breakdown of academic impact, for papers by BA Parker Breakdown of academic impact, for papers by Vincent O. Dezentjé Breakdown of academic impact, for papers by Linda P. Briley Breakdown of academic impact, for papers by Sara Margolin Breakdown of academic impact, for papers by Mitul Shah Breakdown of academic impact, for papers by Lang Li Breakdown of academic impact, for papers by Pia Wegman Breakdown of academic impact, for papers by Anne‐Joy M. de Graan Breakdown of academic impact, for papers by Andrea M. Nibbe
Rankless by CCL
2026